New York S04150 mandates the Department of Health to provide any FDA-approved opioid reversal agent formulation and dosage.

New York S04150 amends the mental hygiene law and public health law to ensure the Department of Health makes available any FDA-approved opioid reversal agent formulation and dosage. The bill requires the office to maintain a publicly accessible directory of opioid reversal agents, including distributor addresses, contact information, services offered, special populations served, accepted insurance providers, and hours of operation. The department will cover the cost of any FDA-approved nasal naloxone product, with any cost overruns borne by the purchaser. The bill takes effect immediately.

New York S04150 mandates the Department of Health to provide any FDA-approved opioid reversal agent formulation and dosage.

New York S04150 amends the mental hygiene law and public health law to ensure the Department of Health makes available any FDA-approved opioid reversal agent formulation and dosage. The bill requires the office to maintain a publicly accessible directory of opioid reversal agents, including distributor addresses, contact information, services offered, special populations served, accepted insurance providers, and hours of operation. The department will cover the cost of any FDA-approved nasal naloxone product, with any cost overruns borne by the purchaser. The bill takes effect immediately.